Treatment with H2S donor sodium hydrosulfide (NaHS), prevented nonalcoholic steatohepatitis (NASH) by reducing hepatic triglyceride and cholesterol levels in rodents fed with the MCD diet through increasing peroxisome proliferator-activated receptor alpha (PPARα) and reducing SREBP-1c gene expression in the liver, suggesting an antisteatogenic effect of H2S through the prevention of oxidative stress and inflammation [104]. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatohepatitis.